Schistosoma Mansoni Clinical Trial
Official title:
Parasitologic Impact of Different Mass Drug Administration Strategies Against Schistosoma Mansoni in Endemic Areas of Mwanza Region, Tanzania, Where Prevalence is 25% or Above
The objective of this study is to determine the strategy for mass drug administration (MDA) which provides the greatest reductions in prevalence and intensity of Schistosoma mansoni in school-aged children after 4 years of intervention.
Intestinal schistosomiasis is caused by the blood-dwelling flatworm Schistosoma mansoni. Despite the increasing focus on the use of praziquantel against schistosomiasis infections for the last three decades many areas in Sub-Saharan Africa still have high prevalences and intensities of schistosomiasis especially among school-age children. This is true for the area of Mwanza Region of Tanzania adjacent to Lake Victoria. The study is a six arm study and includes 150 communities (25 in each arm). From each community 100 school children (aged 9-12 years), 100 first year students (aged 7-8 years) and 50 adults (aged 20-55 years) are included, diagnosed and treated with praziquantel using strategies composing of a mixture of community wide treatment (CWT), school-based treatment (SBT) and years without treatment (-T). The 100 school children provided stool specimens on three consecutive days, while the 100 first year students and 50 adults with few exceptions only provided one specimen. The treatment strategies during the 4 years for the different arms are as follows: Arm 1: CWT, CWT, CWT, CWT; Arm 2: CWT, CWT, SBT, SBT; Arm 3: CWT, CWT -T, -T; Arm 4: SBT, SBT, SBT, SBT; Arm 5: SBT, SBT, -T, -T; Arm 6: SBT, -T, SBT, -T. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05999825 -
Sm-p80 Schistosomiasis Challenge Study
|
Phase 2 | |
Active, not recruiting |
NCT03910972 -
Sm-TSP-2 Schistosomiasis Vaccine in Healthy Ugandan Adults
|
Phase 1/Phase 2 | |
Completed |
NCT05085470 -
Repeated Controlled Human Schistosoma Mansoni Infection
|
N/A | |
Completed |
NCT02755324 -
Single-sex Controlled Human Schistosomiasis Infection: Safety and Dose Finding
|
N/A | |
Completed |
NCT01054651 -
A Randomised Trial of Artesunate-sulfamethoxypyrazine/Pyrimethamine Versus Praziquantel for the Treatment of S. Mansoni
|
Phase 3 | |
Completed |
NCT03893097 -
Evaluation of Artesunate-mefloquine as a Novel Alternative Treatment for Schistosomiasis in African Children
|
Phase 3 | |
Completed |
NCT04679831 -
Clinical Evaluation of Ujiplus® Against Schistosoma Mansoni
|
Phase 2/Phase 3 | |
Withdrawn |
NCT02810613 -
Leiden University Medical Center Mini Donor Bank
|
N/A | |
Recruiting |
NCT06311344 -
Filling Key Research Gaps With Clinical Implications in Mansonellosis and Schistosomiasis: a Network Approach
|
N/A |